- Home
- LQDT vs ABUS Comparison
LQDT vs ABUS Comparison
Compare LQDT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDT
- ABUS
- Stock Information
- Founded
- LQDT 1999
- ABUS 2005
- Country
- LQDT United States
- ABUS United States
- Employees
- LQDT N/A
- ABUS N/A
- Industry
- LQDT Catalog/Specialty Distribution
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- LQDT Consumer Discretionary
- ABUS Health Care
- Exchange
- LQDT Nasdaq
- ABUS Nasdaq
- Market Cap
- LQDT 862.5M
- ABUS 711.2M
- IPO Year
- LQDT 2006
- ABUS N/A
- Fundamental
- Price
- LQDT $27.82
- ABUS $4.39
- Analyst Decision
- LQDT Strong Buy
- ABUS Strong Buy
- Analyst Count
- LQDT 2
- ABUS 2
- Target Price
- LQDT $38.50
- ABUS $5.00
- AVG Volume (30 Days)
- LQDT 189.2K
- ABUS 1.6M
- Earning Date
- LQDT 08-07-2025
- ABUS 11-05-2025
- Dividend Yield
- LQDT N/A
- ABUS N/A
- EPS Growth
- LQDT 33.77
- ABUS N/A
- EPS
- LQDT 0.83
- ABUS N/A
- Revenue
- LQDT $465,508,000.00
- ABUS $15,416,000.00
- Revenue This Year
- LQDT $31.57
- ABUS $138.02
- Revenue Next Year
- LQDT $2.58
- ABUS N/A
- P/E Ratio
- LQDT $33.64
- ABUS N/A
- Revenue Growth
- LQDT 38.40
- ABUS 53.23
- 52 Week Low
- LQDT $21.23
- ABUS $2.71
- 52 Week High
- LQDT $39.72
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- LQDT 62.82
- ABUS 62.06
- Support Level
- LQDT $26.12
- ABUS $4.37
- Resistance Level
- LQDT $28.72
- ABUS $5.10
- Average True Range (ATR)
- LQDT 0.62
- ABUS 0.27
- MACD
- LQDT 0.06
- ABUS 0.01
- Stochastic Oscillator
- LQDT 68.49
- ABUS 50.69
About LQDT Liquidity Services Inc.
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.